Zhang Huikai, Yuan Fanen, Qi Yangzhi, Liu Baohui, Chen Qianxue
Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Front Oncol. 2021 Mar 10;11:607150. doi: 10.3389/fonc.2021.607150. eCollection 2021.
Liquid biopsy has entered clinical applications for several cancers, including metastatic breast, prostate, and colorectal cancer for CTC enumeration and NSCLC for EGFR mutations in ctDNA, and has improved the individualized treatment of many cancers, but relatively little progress has been made in validating circulating biomarkers for brain malignancies. So far, data on circulating tumor cells about glioma are limited, the application of circulating tumor cells as biomarker for glioma patients has only just begun. This article reviews the research status and application prospects of circulating tumor cells in gliomas. Several detection methods and research results of circulating tumor cells about clinical research in gliomas are briefly discussed. The wide application prospect of circulating tumor cells in glioma deserves further exploration, and the research on more sensitive and convenient detection methods is necessary.
液体活检已应用于多种癌症的临床实践，包括用于循环肿瘤细胞（CTC）计数的转移性乳腺癌、前列腺癌和结直肠癌，以及用于检测循环肿瘤DNA（ctDNA）中表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC），并改善了多种癌症的个体化治疗，但在验证脑恶性肿瘤的循环生物标志物方面进展相对较小。到目前为止，关于胶质瘤循环肿瘤细胞的数据有限，将循环肿瘤细胞作为胶质瘤患者生物标志物的应用才刚刚开始。本文综述了循环肿瘤细胞在胶质瘤中的研究现状和应用前景。简要讨论了胶质瘤临床研究中循环肿瘤细胞的几种检测方法和研究结果。循环肿瘤细胞在胶质瘤中的广泛应用前景值得进一步探索，开展更灵敏、便捷检测方法的研究很有必要。
